Check-Cap Ltd. (CHEK) Analysts See $-0.14 EPS

March 14, 2018 - By Vivian Currie

 Check Cap Ltd. (CHEK) Analysts See $ 0.14 EPS

Analysts expect Check-Cap Ltd. (NASDAQ:CHEK) to report $-0.14 EPS on March, 15.They anticipate $0.01 EPS change or 6.67 % from last quarter’s $-0.15 EPS. After having $-0.13 EPS previously, Check-Cap Ltd.’s analysts see 7.69 % EPS growth. The stock increased 4.41% or $0.03 during the last trading session, reaching $0.71. About 284,389 shares traded or 8.27% up from the average. Check-Cap Ltd. (NASDAQ:CHEK) has declined 2.26% since March 14, 2017 and is downtrending. It has underperformed by 18.96% the S&P500.

Check-Cap Ltd. (NASDAQ:CHEK) Ratings Coverage

Among 4 analysts covering Check-Cap (NASDAQ:CHEK), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Check-Cap had 12 analyst reports since July 22, 2015 according to SRatingsIntel. On Thursday, January 11 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was initiated on Thursday, October 8 by Maxim Group. Chardan Capital Markets maintained the stock with “Buy” rating in Friday, May 20 report. Chardan Capital Markets maintained Check-Cap Ltd. (NASDAQ:CHEK) rating on Wednesday, March 16. Chardan Capital Markets has “Buy” rating and $6 target. The rating was initiated by Rodman & Renshaw with “Buy” on Thursday, January 19. The rating was maintained by Maxim Group with “Buy” on Tuesday, January 19. The stock of Check-Cap Ltd. (NASDAQ:CHEK) has “Buy” rating given on Friday, August 11 by H.C. Wainwright. As per Tuesday, May 30, the company rating was maintained by Maxim Group. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, November 28. The rating was maintained by Chardan Capital Markets on Wednesday, July 22 with “Buy”.

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. The company has market cap of $13.68 million. The Company’s C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. It currently has negative earnings.

More notable recent Check-Cap Ltd. (NASDAQ:CHEK) news were published by: which released: “Check-Cap Ltd. Announces Closing of $2.5 Million Registered Direct Offering” on November 22, 2017, also with their article: “Check-Cap Announces Acceptance of Late Breaking Clinical Performance Abstract …” published on October 24, 2017, published: “Check-Cap Ltd. Announces $2.5 Million Registered Direct Offering” on November 20, 2017. More interesting news about Check-Cap Ltd. (NASDAQ:CHEK) were released by: and their article: “Check-Cap Ltd. Announces Closing of $2.69 Million Financing” published on June 02, 2017 as well as‘s news article titled: “Check-Cap Initiates EU Post Approval Study Using Advanced C-ScanĀ®” with publication date: March 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.